KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kura Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$9.36+0.28 (+3.08%)
Close on Oct 19, 2026
- Market cap
- $831.68M
- P/E (TTM)
- –
- Dividend yield
- –
Kura Oncology, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Collaboration revenue | $65.35M | $53.88M | $0 | 96.8% | +21.3% |
| Collaboration Revenue [Member] | $65.35M | $53.88M | – | 96.8% | +21.3% |
| Product [Member] | $2.13M | $0 | $0 | 3.2% | – |
By region
From the segment and revenue-disaggregation notes of Kura Oncology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.